Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

The drug has demonstrated anti-tumor activity and good tolerability in clinical trials ... cancer and other tumor types, today announced that an abstract has been accepted for poster presentation ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a ...

The second poster will include background and study design for the ongoing HEROEX-1 Phase 1a/1b clinical trial (NCT06521554 ... positive non-small cell lung cancer (NSCLC) who have been ...

Researchers at City of Hope will present more than 74 chaired, plenary, educational, minisymposium, poster and other sessions on innovative clinical trial results, breakthrough diagnostic techniques ...

The full abstract will be available on the ASCO® website on May 22, 2025, at 5:00 p.m. ET.

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses ...

These include: (1) a poster presentation of Abdera’s ongoing Phase 1 clinical trial for ABD-147 ... with poor outcomes across multiple cancer types and we look forward to advancing ABD-320 ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a ...

Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS071 ...